IL263505B - קרבונוקליאוזידים מותמרים ושימוש בהם לטיפול בסרטן - Google Patents

קרבונוקליאוזידים מותמרים ושימוש בהם לטיפול בסרטן

Info

Publication number
IL263505B
IL263505B IL263505A IL26350518A IL263505B IL 263505 B IL263505 B IL 263505B IL 263505 A IL263505 A IL 263505A IL 26350518 A IL26350518 A IL 26350518A IL 263505 B IL263505 B IL 263505B
Authority
IL
Israel
Prior art keywords
anticancer agents
derivatives useful
substituted
carbonucleoside derivatives
substituted carbonucleoside
Prior art date
Application number
IL263505A
Other languages
English (en)
Other versions
IL263505A (he
Inventor
Howard Tatlock John
Arnold Kumpf Robert
James Mcalpine Indrawan
Ann Mctigue Michele
Patman Ryan
Yuanjin Rui Eugene
Bich Tran-Dube Michelle
James Wythes Martin
Original Assignee
Pfizer
Howard Tatlock John
Arnold Kumpf Robert
James Mcalpine Indrawan
Ann Mctigue Michele
Patman Ryan
Yuanjin Rui Eugene
Michelle Bich Tran Dube
James Wythes Martin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Howard Tatlock John, Arnold Kumpf Robert, James Mcalpine Indrawan, Ann Mctigue Michele, Patman Ryan, Yuanjin Rui Eugene, Michelle Bich Tran Dube, James Wythes Martin filed Critical Pfizer
Publication of IL263505A publication Critical patent/IL263505A/he
Publication of IL263505B publication Critical patent/IL263505B/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/34—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Silicon Polymers (AREA)
IL263505A 2016-06-06 2018-12-05 קרבונוקליאוזידים מותמרים ושימוש בהם לטיפול בסרטן IL263505B (he)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346226P 2016-06-06 2016-06-06
US201662376856P 2016-08-18 2016-08-18
US201662431714P 2016-12-08 2016-12-08
US201762506076P 2017-05-15 2017-05-15
PCT/IB2017/053295 WO2017212385A1 (en) 2016-06-06 2017-06-03 Substituted carbonucleoside derivatives useful as anticancer agents

Publications (2)

Publication Number Publication Date
IL263505A IL263505A (he) 2019-01-31
IL263505B true IL263505B (he) 2021-04-29

Family

ID=59071035

Family Applications (2)

Application Number Title Priority Date Filing Date
IL263505A IL263505B (he) 2016-06-06 2018-12-05 קרבונוקליאוזידים מותמרים ושימוש בהם לטיפול בסרטן
IL282167A IL282167A (he) 2016-06-06 2021-04-08 קרבונוקליאוזידים מותמרים ושימוש בהם לטיפול בסרטן

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL282167A IL282167A (he) 2016-06-06 2021-04-08 קרבונוקליאוזידים מותמרים ושימוש בהם לטיפול בסרטן

Country Status (42)

Country Link
US (2) US10220037B2 (he)
EP (1) EP3464249B1 (he)
JP (2) JP6553825B2 (he)
KR (2) KR102215313B1 (he)
CN (1) CN109890797B (he)
AU (2) AU2017279014B2 (he)
BR (1) BR112018075166A2 (he)
CA (1) CA2969295A1 (he)
CL (1) CL2018003504A1 (he)
CO (1) CO2018013105A2 (he)
CR (1) CR20180578A (he)
CU (1) CU24517B1 (he)
CY (1) CY1124798T1 (he)
DK (1) DK3464249T3 (he)
DO (1) DOP2018000268A (he)
EC (1) ECSP18090743A (he)
ES (1) ES2890435T3 (he)
GE (1) GEP20217211B (he)
HR (1) HRP20211449T1 (he)
HU (1) HUE056634T2 (he)
IL (2) IL263505B (he)
LT (1) LT3464249T (he)
MA (1) MA45153B1 (he)
MD (1) MD3464249T2 (he)
MX (1) MX2018015094A (he)
MY (1) MY196413A (he)
NI (1) NI201800128A (he)
PE (1) PE20190439A1 (he)
PH (1) PH12018502535A1 (he)
PL (1) PL3464249T3 (he)
PT (1) PT3464249T (he)
RS (1) RS62351B1 (he)
RU (1) RU2712944C1 (he)
SG (2) SG11201810485SA (he)
SI (1) SI3464249T1 (he)
SV (1) SV2018005794A (he)
TN (1) TN2018000424A1 (he)
TW (2) TWI637945B (he)
UA (1) UA124386C2 (he)
UY (1) UY37274A (he)
WO (1) WO2017212385A1 (he)
ZA (1) ZA201807723B (he)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7328218B2 (ja) 2017-10-26 2023-08-16 プレリュード セラピューティクス，インコーポレイティド タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
US20200369667A1 (en) * 2017-12-05 2020-11-26 Angex Pharmaceutical, Inc. Heterocyclic compounds as prmt5 inhibitors
CN108997309A (zh) * 2018-07-17 2018-12-14 中国科学技术大学苏州研究院 一种吡唑-4-芳基衍生物的制备方法
EP3833669A4 (en) * 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
TWI732431B (zh) 2019-01-23 2021-07-01 美商輝瑞股份有限公司 多形體
MX2021011606A (es) 2019-04-02 2021-12-10 Aligos Therapeutics Inc Compuestos dirigidos a prmt5.
JP2022534998A (ja) * 2019-05-30 2022-08-04 エンジェクス ファーマシューティカル インコーポレイテッド Ｐｒｍｔ５阻害剤としての複素環式化合物
CN114026094B (zh) 2019-06-10 2024-06-25 印度鲁宾有限公司 Prmt5抑制剂
MX2022007643A (es) * 2019-12-18 2022-07-19 Pfizer Regimen de tratamiento del cancer una vez por dia con un inhibidor de prmt5.
CN114929234A (zh) * 2020-01-07 2022-08-19 辉瑞公司 用于治疗银屑病及其他自体免疫性病况的方法中的prmt5抑制剂
CN111138355A (zh) * 2020-01-17 2020-05-12 成都睿智化学研究有限公司 一种甲醛取代的氮杂稠环类化合物的制备方法
WO2021152055A1 (en) 2020-01-31 2021-08-05 Solvay Sa Process for the manufacture of haloalkyl substituted pyridine compounds
US20220112194A1 (en) * 2020-04-01 2022-04-14 Aligos Therapeutics, Inc. Compounds targeting prmt5
US20240116937A1 (en) 2020-07-15 2024-04-11 Pfizer Inc. Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
US20230242539A1 (en) 2020-07-15 2023-08-03 Pfizer Inc. Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
CN113234079B (zh) * 2021-04-30 2022-02-01 上海湃隆生物科技有限公司 用作prmt5抑制剂的核苷类似物
WO2024118943A2 (en) * 2022-11-30 2024-06-06 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
BR0207166A (pt) 2001-02-22 2004-02-10 Celltech R&D Ltd Composto, e, composição farmacêutica
US20040043959A1 (en) * 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
EP1987717A1 (de) 2007-04-30 2008-11-05 Bayer CropScience AG Pyridoncarboxamide, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
WO2010100475A1 (en) 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
US9216981B2 (en) * 2010-12-02 2015-12-22 Medpacto, Inc. Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against Raf kinase, containing same as active ingredient
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
US20160168185A1 (en) 2013-07-22 2016-06-16 Baylor College Of Medicine Non-ribose containing inhibitors of histone methyltransferase dot1l for cancer treatment
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
KR102499727B1 (ko) * 2015-02-25 2023-02-15 아웃센스 다이아그나스틱스 엘티디. 신체 배출물 분석
TWI730980B (zh) 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物

Also Published As

Publication number Publication date
IL282167A (he) 2021-05-31
EP3464249B1 (en) 2021-08-11
JP2019521100A (ja) 2019-07-25
BR112018075166A2 (pt) 2019-03-26
KR20210018529A (ko) 2021-02-17
RS62351B1 (sr) 2021-10-29
PH12018502535B1 (en) 2019-10-21
SV2018005794A (es) 2019-03-19
LT3464249T (lt) 2021-10-11
EP3464249A1 (en) 2019-04-10
ECSP18090743A (es) 2019-01-31
HRP20211449T1 (hr) 2021-12-24
DOP2018000268A (es) 2019-01-31
MA45153A (fr) 2021-04-07
WO2017212385A1 (en) 2017-12-14
GEP20217211B (en) 2021-01-25
CR20180578A (es) 2019-03-05
DK3464249T3 (da) 2021-09-06
SI3464249T1 (sl) 2021-11-30
US20170348313A1 (en) 2017-12-07
JP2019194231A (ja) 2019-11-07
TW201802074A (zh) 2018-01-16
US20190111060A1 (en) 2019-04-18
CN109890797A (zh) 2019-06-14
KR20190015745A (ko) 2019-02-14
HUE056634T2 (hu) 2022-02-28
AU2017279014B2 (en) 2019-08-15
MA45153B1 (fr) 2021-10-29
CU20180144A7 (es) 2019-07-04
AU2017279014A1 (en) 2018-12-13
TWI667240B (zh) 2019-08-01
NI201800128A (es) 2019-04-08
IL263505A (he) 2019-01-31
TWI637945B (zh) 2018-10-11
SG10202100861TA (en) 2021-03-30
CN109890797B (zh) 2023-02-28
US10220037B2 (en) 2019-03-05
CY1124798T1 (el) 2022-11-25
CU24517B1 (es) 2021-06-08
PE20190439A1 (es) 2019-03-27
CO2018013105A2 (es) 2018-12-28
AU2019264640A1 (en) 2019-12-05
UA124386C2 (uk) 2021-09-08
US10709709B2 (en) 2020-07-14
MX2018015094A (es) 2019-08-16
SG11201810485SA (en) 2018-12-28
MD3464249T2 (ro) 2021-12-31
NZ748652A (en) 2021-06-25
TW201840570A (zh) 2018-11-16
JP6553825B2 (ja) 2019-07-31
TN2018000424A1 (en) 2020-06-15
PT3464249T (pt) 2021-09-22
ES2890435T3 (es) 2022-01-19
PH12018502535A1 (en) 2019-10-21
MY196413A (en) 2023-03-29
KR102215313B1 (ko) 2021-02-17
RU2712944C1 (ru) 2020-02-03
UY37274A (es) 2018-01-31
PL3464249T3 (pl) 2021-12-20
ZA201807723B (en) 2020-01-29
CL2018003504A1 (es) 2019-02-01
CA2969295A1 (en) 2017-12-06

Similar Documents

Publication Publication Date Title
IL282167A (he) קרבונוקליאוזידים מותמרים ושימוש בהם לטיפול בסרטן
ZA201705092B (en) Substituted nucleoside derivatives useful as anticancer agents
HK1255045A1 (zh) 取代的氧代吡啶衍生物
HK1244803A1 (zh) 作為抗癌藥物的取代的2-氫-吡唑衍生物
IL253381A0 (he) תולדות h9-פירולו-דיפירידין
HRP20190107T1 (hr) Supstituirani 2,4 diamino-kinolin kao novi antikancerogeni agens
ZA202002898B (en) Anticancer agents
IL263157A (he) תכשירים נגד סרטן
ZA202006147B (en) Anticancer compounds
EP3515904C0 (en) BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS
EP3207036A4 (en) Novel small molecule anticancer agents
IL251005B (he) נגזרות של פירידו–אוקסזינון
EP3481806C0 (en) 4-ANILINO-QUINOLINE COMPOUNDS AS ANTI-CANCER AGENTS
IL247868B (he) תולדות פנילפיפרידינקרבוקסאמיד כקוטלי פטריות
HK1253336A1 (zh) 吲哚並吡咯啉抗腫瘤藥物
GB201720279D0 (en) Anticancer compounds
PT3319956T (pt) Derivados de oxopiridina substituída

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed